{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:36:18Z","timestamp":1787027778462,"version":"build-2736575974"},"reference-count":31,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Stereotactic body radiotherapy (SBRT) for prostate cancer delivers high doses in few fractions but poses challenges in sparing adjacent organs at risk (OARs), particularly the intra-prostate urethra, bladder, rectum and penile bulb. Magnetic resonance-guided radiotherapy (MRgRT) using MR-Linac offers superior soft-tissue visualization and daily adaptive planning, potentially reducing OAR dose while maintaining target coverage. This study aimed to compare dose\u2013volume parameters among MR-Linac (ML), volumetric modulated arc therapy (VMAT), and Tomotherapy (HT) plans for prostate SBRT. Methods: Thirty patients with localized prostate cancer were retrospectively analyzed. For each patient, three plans were generated: ML, VMAT and HT, using identical prescription and planning objectives. Dose\u2013volume histogram (DVH) metrics were evaluated for clinical target volume (CTV), planning target volume (PTV), and OARs. Statistical comparisons were performed using non-parametric Friedman\u2019s Test with post hoc Bonferroni test, with significance set at a p &lt; 0.05. Results: CTV coverage was comparable across all modalities. ML achieved significantly higher PTV Dmin and near-maximum doses compared to VMAT and HT. Notably, ML provided substantial urethral sparing, reducing Dmax and Dmean by approximately 3.3 Gy compared to both VMAT and HT (p &lt; 0.001). Rectal dose metrics were also lower with ML, while bladder and penile bulb doses showed minor increases (&lt;3.5 Gy), considered clinically negligible. Femoral head doses were reduced in ML plans. Conclusions: MR-Linac planning for prostate SBRT offers meaningful dosimetric advantages, particularly in intra-prostate urethra urethral dose reduction, without compromising target coverage. These findings support incorporating MR-guided adaptive workflows into SBRT protocols to enhance OAR protection and potentially reduce treatment-related toxicity.<\/jats:p>","DOI":"10.3390\/cancers18040568","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T14:05:15Z","timestamp":1770645915000},"page":"568","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["MR-Linac\u2013Based SBRT for Prostate Cancer: Dosimetric Benefits for Urethral Sparing Compared to VMAT and Tomotherapy"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4618-7865","authenticated-orcid":false,"given":"Eva Y. W.","family":"Cheung","sequence":"first","affiliation":[{"name":"Department of Diagnostic Radiology, LKS Faculty of Medicine, University of Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6226-0743","authenticated-orcid":false,"given":"Darren M. C.","family":"Poon","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Hong Kong Sanatorium and Hospital, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin C. K.","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Hong Kong Sanatorium and Hospital, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee W. S.","family":"Ma","sequence":"additional","affiliation":[{"name":"School of Medical and Health Sciences, Tung Wah College, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessie S. Y.","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Hong Kong Sanatorium and Hospital, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Nip","sequence":"additional","affiliation":[{"name":"School of Medical and Health Sciences, Tung Wah College, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie N. K.","family":"Lam","sequence":"additional","affiliation":[{"name":"School of Medical and Health Sciences, Tung Wah College, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. P.","family":"Fong","sequence":"additional","affiliation":[{"name":"School of Medical and Health Sciences, Tung Wah College, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e188006","DOI":"10.1001\/jamanetworkopen.2018.8006","article-title":"Long-Term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer","volume":"2","author":"Kishan","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","article-title":"Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients with Low-Risk Prostate Cancer","volume":"34","author":"Lee","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1200\/JCO.2020.38.6_suppl.325","article-title":"Eight-Year Outcomes of a Phase III Randomized Trial of Conventional versus Hypofractionated High-Dose Intensity Modulated Radiotherapy for Prostate Cancer (CRUK\/06\/016): Update from the CHHiP Trial","volume":"38","author":"Dearnaley","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1007\/s11547-023-01624-7","article-title":"Linac-Based versus MR-Guided SBRT for Localized Prostate Cancer: A Comparative Evaluation of Acute Tolerability","volume":"128","author":"Nicosia","year":"2023","journal-title":"Radiol. Medica"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Ng, J., Gregucci, F., Pennell, R.T., Nagar, H., Golden, E.B., Knisely, J.P.S., Sanfilippo, N.J., and Formenti, S.C. (2023). MRI-LINAC: A Transformative Technology in Radiation Oncology. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1117874"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/pro6.1143","article-title":"Advances in MRI-guided Precision Radiotherapy","volume":"6","author":"Liu","year":"2022","journal-title":"Precis. Radiat. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Westley, R.L., Alexander, S.E., Goodwin, E., Dunlop, A., Nill, S., Oelfke, U., McNair, H.A., and Tree, A.C. (2024). Magnetic Resonance Image-Guided Adaptive Radiotherapy Enables Safe CTV-to-PTV Margin Reduction in Prostate Cancer: A Cine MRI Motion Study. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1379596"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.3390\/curroncol31050203","article-title":"Online Adaptive MR-Guided Ultrahypofractionated Radiotherapy of Prostate Cancer on a 1.5 T MR-Linac: Clinical Experience and Prospective Evaluation","volume":"31","author":"Potkrajcic","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-Modulated Fractionated Radiotherapy versus Stereotactic Body Radiotherapy for Prostate Cancer (PACE-B): Acute Toxicity Findings from an International, Randomised, Open-Label, Phase 3, Non-Inferiority Trial","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ijrobp.2025.04.039","article-title":"PSMA MRI Guided prOstate SBRT (ARGOS)\/Comprehensive, Longitudinal Evaluation of IMaging BiomarkErs Post Radiotherapy (CLIMBER) Phase I\/II Trial","volume":"123","author":"Ramadan","year":"2025","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Wolfe, S., Diven, M.A., Marciscano, A.E., Zhou, X.K., Kishan, A.U., Steinberg, M.L., Miccio, J.A., Camilleri, P., and Nagar, H. (2023). A Randomized Phase II Trial of MR-Guided Prostate Stereotactic Body Radiotherapy Administered in 5 or 2 Fractions for Localized Prostate Cancer (FORT). BMC Cancer, 23.","DOI":"10.1186\/s12885-023-11430-z"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijrobp.2021.06.037","article-title":"Radiation Dose to the Intraprostatic Urethra Correlates Strongly with Urinary Toxicity After Prostate Stereotactic Body Radiation Therapy: A Combined Analysis of 23 Prospective Clinical Trials","volume":"112","author":"Leeman","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"103","DOI":"10.12809\/hkjr1715378","article-title":"Using the Roach Formula to Stratify Patients with Localised Prostate Cancer Treated with Intensity-Modulated Radiotherapy","volume":"20","author":"Chan","year":"2017","journal-title":"Hong Kong J. Radiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"6829875","DOI":"10.1155\/2016\/6829875","article-title":"Prostate Cancer Radiation Therapy: What Do Clinicians Have to Know?","volume":"2016","author":"Vanneste","year":"2016","journal-title":"BioMed Res. Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s13014-020-01681-6","article-title":"Strict Bladder Filling and Rectal Emptying during Prostate SBRT: Does It Make a Dosimetric or Clinical Difference?","volume":"15","author":"Byun","year":"2020","journal-title":"Radiat. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00066-018-1338-7","article-title":"Phase II Study of Accelerated Linac-Based SBRT in Five Consecutive Fractions for Localized Prostate Cancer","volume":"195","author":"Alongi","year":"2019","journal-title":"Strahlenther. Onkol."},{"key":"ref_17","first-page":"e34351","article-title":"The Association of Radiation Dose with Overall Survival for Patients Treated with Prostate Stereotactic Body Radiation Therapy","volume":"15","author":"Waters","year":"2023","journal-title":"Cureus"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13014-022-02037-y","article-title":"A Phase II Trial of Stereotactic Body Radiotherapy in 4 Fractions for Patients with Localized Prostate Cancer","volume":"17","author":"Kawakami","year":"2022","journal-title":"Radiat. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1200\/JCO.18.01097","article-title":"Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline","volume":"36","author":"Morgan","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"194","DOI":"10.4103\/0971-6203.56078","article-title":"Commissioning Experience and Quality Assurance of Helical Tomotherapy Machines","volume":"34","author":"Sen","year":"2009","journal-title":"J. Med. Phys."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"20190792","DOI":"10.1259\/bjr.20190792","article-title":"Helical Tomotherapy with a Complete-Directional-Complete Block Technique Effectively Reduces Cardiac and Lung Dose for Left-Sided Breast Cancer","volume":"93","author":"Yeh","year":"2020","journal-title":"Br. J. Radiol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Cheung, E.Y.W., Ng, S.S.H., Yung, S.H.Y., Cheng, D.Y.T., Chan, F.Y.C., and Cheng, J.K.Y. (2022). Multi-Planar VMAT Plans for High-Grade Glioma and Glioblastoma Targeting the Hypothalamic-Pituitary Axis Sparing. Life, 12.","DOI":"10.3390\/life12020195"},{"key":"ref_23","first-page":"20210009","article-title":"Non-Coplanar VMAT Plans for Postoperative Primary Brain Tumour to Reduce Dose to Hippocampus, Temporal Lobe and Cochlea: A Planning Study","volume":"3","author":"Cheung","year":"2021","journal-title":"BJR Open"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4103\/0971-6203.103606","article-title":"Homogeneity Index: An Objective Tool for Assessment of Conformal Radiation Treatments","volume":"37","author":"Kataria","year":"2012","journal-title":"J. Med. Phys."},{"key":"ref_25","first-page":"NP","article-title":"Report 62","volume":"os32","author":"Landberg","year":"1999","journal-title":"J. Int. Comm. Radiat. Units Meas."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"20210800","DOI":"10.1259\/bjr.20210800","article-title":"MR-Guided Radiotherapy for Prostate Cancer: State of the Art and Future Perspectives","volume":"95","author":"Sritharan","year":"2022","journal-title":"Br. J. Radiol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Gelbart Pridan, O., Ben David, M.A., Zalmanov, S., Lipski, Y., Grinberg, V., Levin, D., Apter, S., Guindi, M., Epstein, D., and Radus, R. (2023). Outcome of the First 200 Patients with Prostate Cancer Treated with MRI-Linac at Assuta MC. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1151256"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13014-021-01858-7","article-title":"Dosimetric Comparison of MR-Linac-Based IMRT and Conventional VMAT Treatment Plans for Prostate Cancer","volume":"16","author":"Nierer","year":"2021","journal-title":"Radiat. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.ijrobp.2024.10.028","article-title":"Enhancing Delivery Efficiency on the Magnetic Resonance-Linac: A Comprehensive Evaluation of Prostate Stereotactic Body Radiation Therapy Using Volumetric Modulated Arc Therapy","volume":"122","author":"Snyder","year":"2025","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Poon, D.M.C., Yuan, J., Wong, O.L., Yang, B., Chiu, S.T., Cheung, K.Y., Chiu, G., and Yu, S.K. (2025). Stereotactic Total Ablative Radiotherapy with MR-LINAC for Synchronous Oligometastatic Prostate Cancer. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1607610"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"548","DOI":"10.5603\/rpor.106916","article-title":"Magnetic Resonance-Guided Adaptive Stereotactic Radiotherapy in Prostate Cancer Patients: A Systematic Literature Review","volume":"30","author":"Szablewska","year":"2025","journal-title":"Rep. Pract. Oncol. Radiother."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/4\/568\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T14:23:05Z","timestamp":1770646985000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/4\/568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["cancers18040568"],"URL":"https:\/\/doi.org\/10.3390\/cancers18040568","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]}}}